Liquidia Corporation
LQDA
Positions held
Your positionsLQDA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Liquidia Corporation is positioned well in the specialty drug manufacturing sector, focusing on innovative therapies that address unmet medical needs, which can lead to significant market opportunities.
- Revenue increased by 29% compared to the prior quarter, reaching $172 million.
- Operating margin expanded to 49.8%, showcasing improved efficiency in operations.
- Despite recent growth, Liquidia's overall financial health is concerning, with a strong sell signal indicating potential risks in the stock.
- The company reported a net income loss of $68.924 million for the year 2025, reflecting ongoing financial challenges.
- The score indicates a bearish trend with a score of -16.00, highlighting negative market sentiment.
Fundamentals
| Market cap | $2.51B | Enterprise value | $2.41B | Trailing P/E | 20.16 | Forward P/E | 11.66 |
| PEG | — | Price / book | 12.79 | Beta | 0.61 | Dividend yield | 0.00% |
| Revenue growth | 18.4% | Earnings growth | — | Gross margin | 92.5% | Operating margin | 49.8% |
| Profit margin | 30.7% | ROE | 131.8% | ROA | 27.0% | Debt / equity | 0.94 |
| Current ratio | 2.31 | Free cash flow | $74.30M | Analyst recommendation | buy | Mean target | $49.67 |
| 52w high | $93.61 | 52w low | $21.94 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $172M | $133M | $92.0M | $54.3M | $8.8M | — |
| Op margin | 49.8% | 46.3% | 21.5% | 3.3% | -424.4% | — |
| Net income | $74.7M | $52.9M | $14.6M | -$3.5M | -$41.6M | — |
| Gross margin | 93.3% | 91.1% | 92.3% | 94.2% | 83.1% | — |
| Gross profit | $160M | $121M | $85.0M | $51.2M | $7.3M | — |
| Operating income | $85.5M | $61.5M | $19.8M | $1.8M | -$37.5M | — |
- Revenue +29% vs prior quarter ($172M vs $133M).
- Gross margin 93.3% (was 91.1% prior quarter).
- Operating margin expanded to 49.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $158M | $14.0M | $17.5M | $15.9M | — |
| Op margin | -32.5% | -866.6% | -419.6% | -243.3% | — |
| Net income | -$68.9M | -$128M | -$78.5M | -$41.0M | — |
| Gross margin | 91.6% | 58.0% | 83.5% | 82.1% | — |
| Gross profit | $145M | $8.1M | $14.6M | $13.1M | — |
| Operating income | -$51.4M | -$121M | -$73.4M | -$38.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access
2026-10-02 · Wells Fargo Downgrades Liquidia to Equalweight From Overweight, Adjusts PT to $30 From $108
2026-10-01 · United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
2026-10-01 · Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
2026-10-01 · Sector Update: Healthcare Stocks Fall Late Afternoon
2026-10-01 · Liquidia Shares Drop After Downgrades From Raymond James, BTIG
2026-10-01 · LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path
2026-10-01 · Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
2026-10-01 · Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute
2026-10-01 · UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
2026-10-01 · United Therapeutics Won Its Patent War and Liquidia Collapsed
Price (daily)
Full chart · RSI · MACD · patterns